EP1572916A4 - Acide nucleique et proteine correspondante 98p4b6 utilises dans le traitement et la detection du cancer - Google Patents
Acide nucleique et proteine correspondante 98p4b6 utilises dans le traitement et la detection du cancerInfo
- Publication number
- EP1572916A4 EP1572916A4 EP03719599A EP03719599A EP1572916A4 EP 1572916 A4 EP1572916 A4 EP 1572916A4 EP 03719599 A EP03719599 A EP 03719599A EP 03719599 A EP03719599 A EP 03719599A EP 1572916 A4 EP1572916 A4 EP 1572916A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- useful
- detection
- treatment
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37038702P | 2002-04-05 | 2002-04-05 | |
| US370387P | 2002-04-05 | ||
| US10/165,044 US20030149531A1 (en) | 2000-12-06 | 2002-06-06 | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US165044 | 2002-06-06 | ||
| US43548002P | 2002-12-20 | 2002-12-20 | |
| US435480P | 2002-12-20 | ||
| PCT/US2003/010462 WO2003087306A2 (fr) | 2002-04-05 | 2003-04-04 | Acide nucleique et proteine correspondante 98p4b6 utilises dans le traitement et la detection du cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1572916A2 EP1572916A2 (fr) | 2005-09-14 |
| EP1572916A4 true EP1572916A4 (fr) | 2007-05-30 |
Family
ID=29255235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03719599A Withdrawn EP1572916A4 (fr) | 2002-04-05 | 2003-04-04 | Acide nucleique et proteine correspondante 98p4b6 utilises dans le traitement et la detection du cancer |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1572916A4 (fr) |
| JP (1) | JP2005534287A (fr) |
| AU (2) | AU2003223469A1 (fr) |
| BR (1) | BR0308953A (fr) |
| CA (1) | CA2481503A1 (fr) |
| MX (1) | MXPA04009728A (fr) |
| NZ (1) | NZ535762A (fr) |
| WO (1) | WO2003087306A2 (fr) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117986A2 (fr) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Conjugues de medicaments anticorps et procedes correspondants |
| PT2489364E (pt) | 2003-11-06 | 2015-04-16 | Seattle Genetics Inc | Compostos de monometilvalina conjugados com anticorpos |
| WO2005079490A2 (fr) * | 2004-02-13 | 2005-09-01 | Nuvelo, Inc. | Procedes de therapie et de diagnostic reposant sur le ciblage de cellules qui expriment les polypeptides steap2 |
| WO2006015165A2 (fr) * | 2004-07-26 | 2006-02-09 | Enzon Pharmaceuticals, Inc. | Gene optimise pour exprimer l'interferon beta |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| WO2011000054A1 (fr) | 2009-07-03 | 2011-01-06 | Avipep Pty Ltd | Immunoconjugués et leurs procédés de production |
| IN2012DN03025A (fr) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
| US9315581B2 (en) | 2009-12-23 | 2016-04-19 | A Vipep Pty Limited | Immuno-conjugates and methods for producing them |
| SI2528625T1 (sl) | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| EP2579897A1 (fr) | 2010-06-08 | 2013-04-17 | Genentech, Inc. | Anticorps et conjugués modifiés par la cystéine |
| WO2012074757A1 (fr) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Conjugués d'anticorps alaninyl-maytansinol |
| JP6038121B2 (ja) | 2011-04-21 | 2016-12-07 | ガーバン インスティテュート オブ メディカル リサーチ | 修飾された可変ドメイン分子及びその製造及び使用の方法ｂ |
| ES2567276T3 (es) | 2011-05-12 | 2016-04-21 | Genentech, Inc. | Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco |
| KR101877598B1 (ko) | 2011-10-14 | 2018-07-11 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
| WO2013130093A1 (fr) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline |
| EP2906250B1 (fr) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Conjugués pyrrolobenzodiazepine-anticorps anti-psma |
| RS58921B1 (sr) | 2012-10-12 | 2019-08-30 | Medimmune Ltd | Pirolobenzodiazepini i njihovi konjugati |
| EP2906297B1 (fr) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Conjugués anticorps - pyrrolobenzodiazépine |
| EP2906298B1 (fr) | 2012-10-12 | 2018-10-03 | ADC Therapeutics SA | Conjugués pyrrolobenzodiazépine-anticorps |
| PT2906253T (pt) | 2012-10-12 | 2018-11-05 | Medimmune Ltd | Conjugados de anticorpo anti-psma de pirrolobenzodiazepina |
| LT2906251T (lt) | 2012-10-12 | 2017-12-11 | Adc Therapeutics Sa | Pirolobenzodiazepino-anti-cd22 antikūno konjugatai |
| MX364328B (es) | 2012-10-12 | 2019-04-23 | Medimmune Ltd | Conjugados del anticuerpo pirrolobenzodiazepina. |
| JP6307519B2 (ja) | 2012-12-21 | 2018-04-04 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンおよびその結合体 |
| AU2013366490B9 (en) | 2012-12-21 | 2018-02-01 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| US20160031887A1 (en) | 2013-03-13 | 2016-02-04 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| NZ710746A (en) | 2013-03-13 | 2018-11-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| SG11201601005XA (en) | 2013-08-12 | 2016-03-30 | Genentech Inc | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054986B1 (fr) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Conjugués anticorps-pyrrolobenzodiazépine |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3054983B1 (fr) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Conjugués anticorps-pyrrolobenzodiazépines |
| WO2015095212A1 (fr) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement |
| WO2015095227A2 (fr) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci |
| CN105873614B (zh) | 2013-12-16 | 2020-10-30 | 基因泰克公司 | 肽模拟化合物及其抗体-药物缀合物 |
| CN106687141A (zh) | 2014-09-10 | 2017-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其缀合物 |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| JP6622293B2 (ja) | 2014-09-12 | 2019-12-18 | ジェネンテック， インコーポレイテッド | アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法 |
| SG11201701128YA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Cysteine engineered antibodies and conjugates |
| WO2016044560A1 (fr) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés |
| MX2017006770A (es) | 2014-11-25 | 2018-02-09 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepina y anticuerpo. |
| WO2016090050A1 (fr) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
| EP3465221B1 (fr) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site |
| EP3464280B1 (fr) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation |
| CN109689111B (zh) | 2016-08-11 | 2024-04-05 | 基因泰克公司 | 吡咯并苯并二氮杂䓬前药及其抗体缀合物 |
| US10772972B2 (en) * | 2016-09-23 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof |
| WO2018065501A1 (fr) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Procédés de préparation de conjugués anticorps-médicament |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| ES2871001T3 (es) | 2017-02-08 | 2021-10-28 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepinas y anticuerpos |
| PT3612537T (pt) | 2017-04-18 | 2022-08-29 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
| JP7408396B2 (ja) | 2017-04-20 | 2024-01-05 | アーデーセー セラピューティクス ソシエテ アノニム | 併用療法 |
| WO2018229222A1 (fr) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Régimes posologiques pour l'administration d'un cam anti-cd19 |
| MY194477A (en) | 2017-08-18 | 2022-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| BR112020004307A2 (pt) | 2017-09-20 | 2020-11-10 | Ph Pharma Co., Ltd. | análogos de tailanestatina |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| CA3115110A1 (fr) | 2018-10-24 | 2020-04-30 | F. Hoffmann-La Roche Ag | Inducteurs chimiques conjugues de degradation et methodes d'utilisation |
| EP3894427A1 (fr) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| WO2021207727A1 (fr) * | 2020-04-10 | 2021-10-14 | Postsurgical Therapeutics, Inc. | Méthodes de thérapie ciblée combinatoire |
| IL299153A (en) | 2020-07-13 | 2023-02-01 | Regeneron Pharma | Camptothecin analogs conjugated to a glutamine residue in protein, and their uses |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| WO2023147328A1 (fr) | 2022-01-26 | 2023-08-03 | Genentech, Inc. | Inducteurs chimiques de dégradation conjugués à des anticorps avec lieurs maléimide hydolysables et méthodes associées |
| WO2023147329A1 (fr) | 2022-01-26 | 2023-08-03 | Genentech, Inc. | Inducteurs chimiques conjugués à des anticorps de dégradation et procédés associés |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001040276A2 (fr) * | 1999-12-06 | 2001-06-07 | Agensys, Inc | Nouveaux antigenes transmembranaires du type serpentin exprimes dans des cancers humains et utilisation de ces antigenes |
| WO2001072962A2 (fr) * | 2000-03-24 | 2001-10-04 | Fahri Saatcioglu | Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique |
-
2003
- 2003-04-04 BR BRPI0308953-3A patent/BR0308953A/pt not_active Application Discontinuation
- 2003-04-04 AU AU2003223469A patent/AU2003223469A1/en not_active Abandoned
- 2003-04-04 WO PCT/US2003/010462 patent/WO2003087306A2/fr active Application Filing
- 2003-04-04 CA CA002481503A patent/CA2481503A1/fr not_active Abandoned
- 2003-04-04 EP EP03719599A patent/EP1572916A4/fr not_active Withdrawn
- 2003-04-04 MX MXPA04009728A patent/MXPA04009728A/es active IP Right Grant
- 2003-04-04 NZ NZ535762A patent/NZ535762A/xx not_active IP Right Cessation
- 2003-04-04 JP JP2003584250A patent/JP2005534287A/ja active Pending
-
2009
- 2009-10-27 AU AU2009230789A patent/AU2009230789A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001040276A2 (fr) * | 1999-12-06 | 2001-06-07 | Agensys, Inc | Nouveaux antigenes transmembranaires du type serpentin exprimes dans des cancers humains et utilisation de ces antigenes |
| WO2001072962A2 (fr) * | 2000-03-24 | 2001-10-04 | Fahri Saatcioglu | Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009230789A1 (en) | 2009-11-19 |
| AU2003223469A1 (en) | 2003-10-27 |
| NZ535762A (en) | 2009-04-30 |
| EP1572916A2 (fr) | 2005-09-14 |
| CA2481503A1 (fr) | 2003-10-23 |
| BR0308953A (pt) | 2006-03-14 |
| WO2003087306A8 (fr) | 2006-10-05 |
| WO2003087306A2 (fr) | 2003-10-23 |
| MXPA04009728A (es) | 2005-06-08 |
| JP2005534287A (ja) | 2005-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1572916A4 (fr) | Acide nucleique et proteine correspondante 98p4b6 utilises dans le traitement et la detection du cancer | |
| AU2003243151A8 (en) | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer | |
| HK1152714A1 (en) | Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer steap-1 | |
| EP1537140A4 (fr) | Acide nucleique et proteine correspondante 161p2f10b utiles dans le traitement et le depistage du cancer | |
| AU2002318112B2 (en) | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers | |
| EP1517606A4 (fr) | Acide nucleique et proteine correspondante appelee 193p1e1b utile dans le traitement et la detection du cancer | |
| EP1622571A4 (fr) | Acides nucleiques et proteines correspondantes appelees 109p1d4 utiles dans le traitement et la detection du cancer | |
| PT1537140E (pt) | Ácido nucleico e proteína correspondente designada 161p2f10b úteis no tratamento e detecção de cancro | |
| EP1372719A4 (fr) | Acide nucleique et proteine correspondante denommes 125p5c8 utiles dans le traitement et la detection de cancers | |
| EP1590437A4 (fr) | Acides nucleiques et proteines correspondantes dites 254p1d6b utiles pour la detection et le traitement du cancer | |
| EP1573023A4 (fr) | Acide nucleique et proteine correspondante nommes 162p1e6 utiles dans la detection et le traitement d'un cancer | |
| AU2002246708A1 (en) | Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer | |
| AU2001285018A1 (en) | Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer | |
| EP1565200A4 (fr) | Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer | |
| EP1578980A4 (fr) | Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer | |
| AU2003268355A8 (en) | Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells | |
| EP1539805A4 (fr) | Acides nucleiques et proteines correspondantes dits 101p3a11 ou phor-1 servant au traitement et a la detection de cancers | |
| EP1545556A4 (fr) | Acide nucleique et proteine correspondante denommes 98p4b6, pour traitement et detection du cancer | |
| EP1399174A4 (fr) | Acide nucleique et proteine correspondante, appelee 121p1f1, utilisee dans le traitement et le depistage du cancer | |
| EP1499350A4 (fr) | Acide nucleique et proteine correspondante appelee 205p1b5 utilises dans le traitement et la detection du cancer | |
| ZA200501838B (en) | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer | |
| IL164390A0 (en) | Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer | |
| AU2001286541A1 (en) | Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer | |
| AU2002305170A1 (en) | Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer | |
| AU2012244341A1 (en) | Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20041025 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1080113 Country of ref document: HK |
|
| PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/00 20060101ALI20070109BHEP Ipc: G01N 33/574 20060101ALI20070109BHEP Ipc: C12Q 1/68 20060101ALI20070109BHEP Ipc: C07K 16/30 20060101ALI20070109BHEP Ipc: C07K 14/705 20060101AFI20070109BHEP |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20070427 |
|
| 17Q | First examination report despatched |
Effective date: 20080730 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20090210 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1080113 Country of ref document: HK |